Alternating electric tumor treating fields for treatment of glioblastoma: Rationale, preclinical, and clinical studies

Journal of Neurosurgery

Volumn 128, Issue 2, 2018, Pages 414-421

  Mittal, Sandeep ^a,b   Klinger, Neil V ^a   Michelhaugh, Sharon K ^a   Barger, Geoffrey R ^a,b   Pannullo, Susan C ^c,d   Juhász, Csaba ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

^d School of Operations Research and Industrial Engineering   (United States)

Author keywords

Alternating electric fields; Newly diagnosed glioblastoma; NovoTTF 100A; Oncology; Optune; Recurrent glioblastoma; Tumor treating fields

Indexed keywords

ANTINEOPLASTIC AGENT;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); ELECTRIC FIELD; ELECTROPHORESIS; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HUMAN; MONOTHERAPY; NEUROSURGERY; NONHUMAN; PATIENT SAFETY; PRECLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE ASSESSMENT; SALVAGE THERAPY; THERAPEUTIC INDEX; THERAPY EFFECT; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; BRAIN TUMOR; ELECTROTHERAPY; PATHOLOGY; PROCEDURES;

BRAIN NEOPLASMS; ELECTRIC STIMULATION THERAPY; GLIOBLASTOMA; HUMANS; TREATMENT OUTCOME;

EID: 85041711871     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2016.9.JNS16452     Document Type: Article

References (28)

1. Ancona A, Arévalo A, Macotela E: Contact dermatitis in hospital patients. Dermatol Clin 8:95-105, 1990
2. Bernard-Arnoux F, Lamure M, Ducray F, Aulagner G, Honnorat J, Armoiry X: The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro Oncol 18:1129-1136, 2016
3. Chaudhry A, Benson L, Varshaver M, Farber O, Weinberg U, Kirson E, et al: NovoTTF"-100A System (Tumor Treating Fields) transducer array layout planning for glioblastoma: a NovoTAL" system user study. World J Surg Oncol 13:316 2015
4. Choy W, Kim W, Nagasawa D, Stramotas S, Yew A, Gopen Q, et al: The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. Neurosurg Focus 30(5):E6, 2011
5. Clague DS, Wheeler EK: Dielectrophoretic manipulation of macromolecules: the electric field. Phys Rev E Stat Nonlin Soft Matter Phys 64:026605 2001
6. Gera N, Yang A, Holtzman TS, Lee SX, Wong ET, Swanson KD: Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit. PLoS One 10:e0125269, 2015
7. Giladi M, Schneiderman RS, Voloshin T, Porat Y, Munster M, Blat R, et al: Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep 5:18046 2015
8. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, et al: Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 31:4085-4091, 2013
9. Keller FJ, Gettys WE, Skove MJ: Physics, Classical and Modern. New York: McGraw-Hill, 1993, Vol 51
10. Kirson ED, Dbalý V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, et al: Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A 104:10152-10157, 2007
11. Kirson ED, Giladi M, Gurvich Z, Itzhaki A, Mordechovich D, Schneiderman RS, et al: Alternating electric fields (TT-Fields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis 26:633-640, 2009
12. Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, et al: Disruption of cancer cell replication by alternating electric fields. Cancer Res 64:3288-3295, 2004
13. Kirson ED, Schneiderman RS, Dbalý V, Tovaryš F, Vymazal J, Itzhaki A, et al: Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys 9:1, 2009
14. Kovic B, Xie F: Economic evaluation of bevacizumab for the first-line treatment of newly diagnosed glioblastoma multi-forme. J Clin Oncol 33:2296-2302, 2015
15. Lacouture ME, Davis ME, Elzinga G, Butowski N, Tran D, Villano JL, et al: Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma. Semin Oncol 41 (Suppl 4):S1-S14, 2014
16. Novocure (USA) Inc: Instructions For Use. NovoTTF-100A System. (http://www.accessdata.fda.gov/cdrh-docs/pdf10/P100034c.pdf) [Accessed December 1, 2016]
17. Pless M, Droege C, von Moos R, Salzberg M, Betticher D: A phase I/II trial of tumor treating fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. Lung Cancer 81:445-450, 2013
18. Rowinsky EK, Donehower RC: Paclitaxel (taxol). N Engl J Med 332:1004-1014, 1995
19. Salzberg M, Kirson E, Palti Y, Rochlitz C: A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors. Onkologie 31:362-365, 2008
20. Schneiderman RS, Shmueli E, Kirson ED, Palti Y: TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that overexpress ABC transporters. BMC Cancer 10:229 2010
21. Stupp R, Idbaih A, Steinberg DM, Read W, Toms S, Barnett G, et al: LTBK-01: Prospective multi-center phase III trial of tumor treating fields together with temozolomide compared with temozolomide alone in patients with newly diagnosed glioblastoma. Neuro Oncol 18 (Suppl 6):i1, 2016 (Abstract)
22. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
23. Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al: Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314:2535-2543, 2015
24. Stupp R, Wong E, Scott C, Taillibert S, Kanner A, Kesari S, et al: Interim analysis of the EF-14 Trial: a prospective, multi-center trial of NovoTTF-100A together with temozolomide compared to temozolomide alone in patients with newly diagnosed GBM. Neuro Oncol 16 (Suppl 5):v167, 2014 (Abstract)
25. Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, et al: NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 48:2192-2202, 2012
26. Turner SG, Gergel T, Wu H, Lacroix M, Toms SA: The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF"-100A system. World J Surg Oncol 12:162 2014
27. United States Food and Drug Administration: FDA approves expanded indication for medical device to treat a form of brain cancer. FDA News Release. October 5, 2015. (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm465744.htm) [Accessed December 1, 2016]
28. Xie Q, Mittal S, Berens ME: Targeting adaptive glioblastoma: an overview of proliferation and invasion. Neuro Oncol 16:1575-1584, 2014